Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Patients with type 2 diabetes who undergo insulin pump therapy achieve a larger reduction in HbA1c than those who remain on a multiple daily insulin injection regimen, according to findings from the OpT2mise trial.
In the trial, researchers evaluated patients with type 2 diabetes aged 35 to 70 years who were on multiple daily injection (MDI) regimens and high insulin doses 90.5-1.8 U/kg/day). The regimens were titrated during a 2-month run-in phase. With the exception of metformin, all oral diabetic medications were discontinued.
Plasma assays for C-peptide and anti-glutamic acid decarboxylase antibody were conducted at baseline and at the end of the study period (6 months). Patients were stratified according to anti-glutamic acid decarboxylase antibody and C-peptide concentrations. Researchers evaluated possible associations between these biomarkers and baseline HbA1c, changes in HbA1c and HbA1c changes related to treatment group assignment.
http://www.healio.com/endocrinology...hba1c-levels-in-patients-with-type-2-diabetes
In the trial, researchers evaluated patients with type 2 diabetes aged 35 to 70 years who were on multiple daily injection (MDI) regimens and high insulin doses 90.5-1.8 U/kg/day). The regimens were titrated during a 2-month run-in phase. With the exception of metformin, all oral diabetic medications were discontinued.
Plasma assays for C-peptide and anti-glutamic acid decarboxylase antibody were conducted at baseline and at the end of the study period (6 months). Patients were stratified according to anti-glutamic acid decarboxylase antibody and C-peptide concentrations. Researchers evaluated possible associations between these biomarkers and baseline HbA1c, changes in HbA1c and HbA1c changes related to treatment group assignment.
http://www.healio.com/endocrinology...hba1c-levels-in-patients-with-type-2-diabetes